NCT06325683 2026-04-15
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
22 trialsNCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT06528691 2026-03-23
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
St. Jude Children's Research Hospital
Phase 2 Recruiting
NCT07053033 2026-03-09
Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05879250 2025-12-30
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 2 Recruiting
NCT02792582 2025-11-12
A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT02981940 2025-09-02
A Study of Abemaciclib in Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03018288 2025-08-08
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04406272 2025-06-10
VB-111 in Surgically Accessible Recurrent/Progressive GBM
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT06328036 2024-12-30
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT02794883 2022-04-18
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
Northwestern University
Phase 2 Completed
NCT01567202 2020-09-09
Study of DC Vaccination Against Glioblastoma
Huashan Hospital
Phase 2 Unknown
NCT01339052 2019-03-19
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01213407 2016-05-19
GBM-Vax
Activartis Biotech
Phase 2 Completed
NCT00238303 2014-05-23
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003122 2013-08-26
Surgery in Treating Patients With Neuroblastoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00870181 2013-06-25
HGG-01
Huazhong University of Science and Technology
Phase 2 Completed
NCT00003574 2013-06-21
Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003467 2013-06-20
Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma
Duke University
Phase 2 Completed
NCT00004024 2013-04-05
Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00515086 2011-09-22
Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)
Novartis
Phase 2 Terminated
NCT00135135 2008-06-03
Therapy for Children With Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed